Anti -AML-1

For Research Use Only. Not for use in diagnostic procedures.

Chromosome: 21; NC_000021.8 (36160098..36421595, complement). Location: 21q22.3

Polyclonal

IgG

Rabbit

Recognizes human AML-1. Species Crossreactivity: Mouse

Affinity Purified
Purified by Protein G affinity chromatography.

Supplied as a liquid in PBS, 0.02% sodium azide.

May be stored at 4 degree C for short-term only. For long-term storage and to avoid repeated freezing and thawing, add sterile glycerol (40-50%), aliquot and store at -20 degree C. Aliquots are stable for at least 12 months at -20 degree C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.

Small volumes of anti-RUNX1 antibody vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

AML-1 is a DNA-binding protein which specifically interacts with a sequence belonging to the group of enhancer core motifs, TGT/cGGT. The AML1 gene on chromosome 21 is disrupted in the (8;21)(q22;q22) translocation associated with acute myelogenous leukemia and encodes a protein with a central 118-amino-acid domain with 69% homology to the Drosophila pair-rule gene, runt. AML-1 translocation is frequently observed in acute myeloid leukemia. It is a key transactivator of tissue-specific genes of the hematopoietic and bone lineages.

Antibodies; Abs to Transcription Factors

Western Blot (WB)

Suitable for use in Western Blot.
Dilution: Western Blot: 2-5ug/ml

48,737 Da[Similar Products]

runt-related transcription factor 1

runt-related transcription factor 1; CBF-alpha-2; PEA2-alpha B; PEBP2-alpha B; aml1 oncogene; oncogene AML-1; OTTHUMP00000108696; OTTHUMP00000108697; OTTHUMP00000108699; OTTHUMP00000108700; OTTHUMP00000108702; AML1-EVI-1 fusion protein; acute myeloid leukemia 1 protein; core-binding factor subunit alpha-2; SL3-3 enhancer factor 1 alpha B subunit; SL3/AKV core-binding factor alpha B subunit; core-binding factor, runt domain, alpha subunit 2; polyomavirus enhancer-binding protein 2 alpha B subunit

Runt-related transcription factor 1

AML1; CBFA2??[Similar Products]

RUNX1_HUMAN

Core binding factor (CBF) is a heterodimeric transcription factor that binds to the core element of many enhancers and promoters. The protein encoded by this gene represents the alpha subunit of CBF and is thought to be involved in the development of normal hematopoiesis. Chromosomal translocations involving this gene are well-documented and have been associated with several types of leukemia. Three transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq]

AML1: CBF binds to the core site, 5'-PYGPYGGT-3', of a number of enhancers and promoters, including murine leukemia virus, polyomavirus enhancer, T-cell receptor enhancers, LCK, IL-3 and GM-CSF promoters. The alpha subunit binds DNA and appears to have a role in the development of normal hematopoiesis. Isoform AML-1L interferes with the transactivation activity of RUNX1. Acts synergistically with ELF4 to transactivate the IL-3 promoter and with ELF2 to transactivate the mouse BLK promoter. Inhibits KAT6B- dependent transcriptional activation. Heterodimer with CBFB. RUNX1 binds DNA as a monomer and through the Runt domain. DNA-binding is increased by heterodimerization. Isoform AML-1L can neither bind DNA nor heterodimerize. Interacts with TLE1 and ALYREF/THOC4. Interacts with ELF1, ELF2 and SPI1. Interacts via its Runt domain with the ELF4 N-terminal region. Interaction with ELF2 isoform 2 (NERF-1a) may act to repress RUNX1-mediated transactivation. Interacts with KAT6A and KAT6B. Interacts with SUV39H1, leading to abrogation of transactivating and DNA-binding properties of RUNX1. Interacts with YAP1. Interacts with HIPK2. Interaction with CDK6 prevents myeloid differentiation, reducing its transcription transactivation activity. Expressed in all tissues examined except brain and heart. Highest levels in thymus, bone marrow and peripheral blood. 11 isoforms of the human protein are produced by alternative splicing.

Protein type: Oncoprotein; Transcription factor; DNA-binding

Chromosomal Location of Human Ortholog: 21q22.3

Cellular Component: nucleoplasm; intracellular membrane-bound organelle; cytoplasm; basement membrane; nucleus

Molecular Function: protein binding; protein homodimerization activity; DNA binding; protein heterodimerization activity; calcium ion binding; transcription factor binding; transcription factor activity; ATP binding

Biological Process: hair follicle morphogenesis; central nervous system development; transcription, DNA-dependent; in utero embryonic development; embryonic hemopoiesis; positive regulation of transcription, DNA-dependent; positive regulation of granulocyte differentiation; regulation of signal transduction; liver development; negative regulation of granulocyte differentiation; peripheral nervous system neuron development; positive regulation of angiogenesis; behavioral response to pain; myeloid progenitor cell differentiation; positive regulation of interleukin-2 production; hemopoiesis; myeloid cell differentiation; positive regulation of transcription from RNA polymerase II promoter; skeletal development

Disease: Platelet Disorder, Familial, With Associated Myeloid Malignancy; Leukemia, Acute Myeloid; Rheumatoid Arthritis

All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.

While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.

It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.